# Adjuvant Therapies for Patients With HCC and MVI

> **NCT02436902** · PHASE3 · UNKNOWN · sponsor: **Guangxi Medical University** · enrollment: 240 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **PROCEDURE:** TACE
- **DRUG:** Sorafenib
- **DRUG:** TACE plus sorafenib
- **OTHER:** empty control

## Key facts

- **NCT ID:** NCT02436902
- **Lead sponsor:** Guangxi Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-02-01
- **Primary completion:** 2022-08-23
- **Final completion:** 2022-08-30
- **Target enrollment:** 240 (ESTIMATED)
- **Last updated:** 2020-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02436902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02436902, "Adjuvant Therapies for Patients With HCC and MVI". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02436902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*